Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: E7080 Clear all

Conditions: Advanced Hepatocellular Carcinoma (HCC)
Interventions: WGI-0301, Lenvatinb; Drug
Lead sponsor: Zhejiang Haichang Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Lenvatinib, Sorafenib; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 18 more

Conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Lenvatinib, Pembrolizumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thyroid Cancer, Cancer of the Thyroid
Interventions: Lenvatinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Renal Cell Carcinoma
Interventions: Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumors
Interventions: Golvatinib, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions: AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay; Biological · Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Lenvatinib, Pembrolizuma, Fulvestrant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Renal Impairment, Disease Severity
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Neoplasms
Interventions: pembrolizumab, lenvatinib, regorafenib, TAS-102 (trifluridine and tipiracil); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more

Conditions: Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Solid Tumor
Interventions: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Urothelial Carcinoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Gilbert, Arizona • Clovis, California • Orange, California + 18 more

Conditions: Cancer, Solid Tumor
Interventions: Eribulin, Lenvatinib; Drug
Lead sponsor: Virginia G. Kaklamani; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
Interventions: Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib; Procedure · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Hematologic Malignancies
Interventions: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 65
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more

Conditions: Carcinoma, Hepatocellular
Interventions: Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE; Drug · Biological · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more

Conditions: Advanced Malignancies
Interventions: Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Miami, Florida • New York, New York • Nashville, Tennessee + 1 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration; Drug · Procedure · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 41
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more

Search by objective public record fields.

A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Eribulin and Lenvatinib in Advanced Solid Tumors

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer